Oxford Biodyn Share News (OBD)

Oxford BioDynamics revenue up 49% in first half as test sales rise

(Alliance News) - Oxford BioDynamics PLC on Tuesday reported strong revenue growth on the back of the increased commercialisation of its EpiSwitch genomics platform.

UK earnings, trading statements calendar - next 7 days

Oxford BioDynamics develops canine cancer test with 89% accuracy

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced the development of a canine cancer diagnostic test based on its EpiSwitch non-invasive platform.

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Oxford BioDynamics to provide tests to largest UK charitable hospital

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Oxford BioDynamics reaches "important milestone" with new laboratory

(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate screening tests.

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

CORRECT: Oxford BioDynamics plunges as annual loss widens; revenue up

(Correcting headline to show loss widened, revenue rose)

CORRECT: Oxford BioDynamics plunge as annual profit rises; revenue up

(Correcting headline to show profit and revenue rose)

Oxford BioDynamics shares plunge as annual revenue widens; revenue up

(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch.

AIM WINNERS & LOSERS: James Cropper falls on lower outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Director dealings: Oxford Biodynamics director lowers stake

(Sharecast News) - Oxford Biodynamics revealed on Friday that Vulpes Testudo Fund had offloaded 777,000 ordinary shares in the AIM-listed biotechnology company.

IN BRIEF: Oxford BioDynamics director sells over 700,000 shares

Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million.